<DOC>
	<DOCNO>NCT01097395</DOCNO>
	<brief_summary>The purpose study determine concentration-controlled ribavirin dose achieve target level plasma exposure appear safe effective compare standard weight-based ribavirin dosing . Forty , previously treatment-naive participant genotype 1 disease randomize receive concentration-guided standard weight-based ribavirin . Peginterferon alfa 2a , ribavirin , telaprevir provide study .</brief_summary>
	<brief_title>Concentration-Controlled Ribavirin Treatment Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Chronic HCVinfected men woman 1870 year HCV genotype 1 Deemed ready HCV treatment hepatology provider patient Allowed medication : specifically list exclusion criterion include medication peginterferon / ribavirin related adverse effect : acetaminophen , ibuprofen , diphenhydramine , selective serotonin reuptake inhibitor , darbepoeitin , erythropoietin , GCSF previous treatment interferon , peginterferon , investigational HCV drug , boceprevir , ribavirin ; baseline absolute neutrophil count ( ANC ) &lt; 1000/mm3 , platelet &lt; 100,000/mm3 , hemoglobin &lt; 12 g/dL woman &lt; 13 g/dL men ; HIV positive serostatus ; HBV positive serostatus ; decompensated liver disease ( i.e. , ascites , history esophageal variceal bleeding , hepatic encephalopathy ) ; autoimmune hepatitis hemoglobinopathy ( e.g. , sickle cell anemia , thalassemia ) Cockcroft Gault estimate creatinine clearance &lt; 50 mL/min ; alcohol illicit drug use opinion investigator would interfere study participation and/or impact study result female , active pregnancy intent become pregnant study period 6 month complete treatment male , pregnant female partner intent impregnate female study period 6 month complete treatment sex unwillingness use two form contraception study period 6 month complete treatment . While telaprevir 2 week follow discontinuation telaprevir , female must use two nonhormonal form contraception ; history significant unstable cardiac disease include severe coronary artery disease ( unstable angina , recent myocardial infarction , chest pain exertion ) congestive heart failure ; receipt organ transplant ; malignant neoplastic disease ; chronic pulmonary disease opinion study hepatologists would preclude treatment peginterferon ribavirin ( e.g. , pulmonary function test â‰¤70 % within previous 2 year ) ; history admission psychiatric facility within previous year ; suicide attempt within previous 3 year ; concomitant medication include : amantadine , mycophenolate mofetil , investigational HCV compound , alfuzosin , alfentanil , ergot derivative ( dihydroergotamine/ergotamine/ergonovine/methylergonovine ) , meperidine , antiarrhythmic ( quinidine , flecainide , propafenone , amiodarone , bepridil ) , astemizole , terfenadine , buspirone , diazepam , estazolam , oral midazolam , triazolam , budesonide , domperidone , eletriptan , eplerenone , fluticasone , pimozide , salmeterol , calcium channel blocker ( diltiazem , felodipine , nifedipine , nisoldipine , verapamil ) , cisapride , cyclosporine , sirolimus , systemic tacrolimus , atorvastatin , lovastatin , simvistatin , sildenafil , tadalafil , verdenafil , antibiotic ( clarithromycin , erythromycin , telithromycin , troleandomycin ) , carbamazepine , Phenobarbital , phenytoin , nefazodone , St. Johns Wort , antifungal ( fluconazole , itraconazole , ketoconazole , posaconazole , voriconazole ) , rifampin , rifabutin , aprepitant , cholestyramine , fluvoxamine , mifepreistone , modafinil , systemic dexamethasone . With exception St. Johns Wort , investigator may use discretion use herbal dietary supplement . Evidence severe retinopathy clinically relevant ophthalmologic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ribavirin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Hepatitis C virus</keyword>
</DOC>